glaucoma
Conditions
Interventions
latanoprost 0.005% including benzalconium chloride preservative 3 months treatment once daily
travoprost 0.004% including SofZia preservative 3 months treatment once daily
Sponsors
public health research foundation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.POAG or OH using latanoprost 0.005% eye drops only over 3 months 2. not applicable for IOP level 3. not wearing contact lenses 4. not applicable for the presence of the ocular surface diseases in case the treatment was not needed
Exclusion criteria
Exclusion criteria: 1. the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection 2. the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6 months 3. the eyes with difficulty for the measurement of IOP with the applanation tonometer 4. the subjects with the allergy for PG-analogues or benzalconium chloride 5. the subjects using the eyedrops excluding those in this study 6. the subjects treated with oral carbonic anhydrase inhibitor 7. the subject with Sjogren syndrome 8. the subjects who can not drop periodically 9. the subjects with the advanced glaucoma or the terminal stage of glaucoma 10. the subjects with the severe ocular complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the damage of corneal and conjunctival epithelium, and conjunctival hyperemia at 1 and 3 months after application of 2 kinds of IOP-lowering eye drops including a different preservative in each solution | — |
Secondary
| Measure | Time frame |
|---|---|
| the change of intraocular pressure at 1 and 3 months after application of 2 kinds of IOP-lowering eye drops including a different preservative in each solution | — |
Countries
Japan
Contacts
Public Contactmakoto aihara
University of Tokyo Hospital ophthalmology
Outcome results
None listed